Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06749730 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Name: Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma — clinical trial record (NCT06749730)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorHenan Cancer Hospital

Started2024-04-01

View on ClinicalTrials.gov ↗

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

Cholangiocarcinoma

611 trials monitored

See 25 trials at risk

This study is designed to combine anti-angiogenic drugs on the basis of PD-L1+ gemcitabine/cisplatin, hoping to further improve the curative effect of advanced BTC treatment and provide more choices for first-line treatment of BTC in China.

Trial Details

NCT Number	NCT06749730
Lead Sponsor	Henan Cancer Hospital
Conditions	Unresectable Biliary Tract Carcinoma
Enrollment	63 participants
Start Date	2024-04-01
Primary Completion	2026-12 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2024-12-27